EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics

F Donelson Smith iD, Robert H Pierce, Thomas Thisted, Edward H van der Horst iD

Antibodies · 30.08.2023 · 12 (3) · 55

DOI: 10.3390/antib12030055 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 30.08.2023. Verfasst von F Donelson Smith und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sensei Biotherapeutics, Inc., 1405 Research Blvd., Suite 125, Rockville, MD 20850, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sensei Biotherapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoints and other immunoregulatory targets can be difficult to precisely target due to expression on non-tumor immune cells critical to maintaining immune homeostasis in healthy tissues. On-target/off-tumor binding of therapeutics results in significant pharmacokinetic and pharmacodynamic problems. Target-mediated drug disposition (TMDD) significantly limits effective intratumoral drug levels and adversely affects anti-tumor efficacy. Target engagement outside the tumor environment may lead to severe immune-related adverse events (irAEs), resulting in a narrowing of the therapeutic window, sub-optimal dosing, or cessation of drug development altogether. Overcoming these challenges has become tractable through recent advances in antibody engineering and screening approaches. Here, we review the discovery and development of conditionally active antibodies with minimal binding to target at physiologic pH but high-affinity target binding at the low pH of the tumor microenvironment by focusing on the discovery and improved properties of pH-dependent mAbs targeting two T cell checkpoints, VISTA and CTLA-4.

Schlagwörter

Stichwörter der Autor:innen

Warburg effectcancer immunotherapyimmune checkpoint inhibitorspH selective antibodies

Autor:innen und Institutionen

  • Sensei Biotherapeutics, Inc., 1405 Research Blvd., Suite 125, Rockville, MD 20850, USA.
  • 282088 US Highway 101, Port Townsend, WA 98368, USA.

ORCID-Profile: F Donelson Smith, Edward H van der Horst

Förderung

  • Sensei Biotherapeutics

Zitieren

APA

Smith, F. D., Pierce, R. H., Thisted, T., & van der Horst, E. H. (2023). Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics. Antibodies, 12(3), 55. https://doi.org/10.3390/antib12030055

Vancouver

Smith FD, Pierce RH, Thisted T, van der Horst EH. Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics. Antibodies. 2023;12(3):55. doi:10.3390/antib12030055

BibTeX
@article{Smith2023,
  author = {Smith, F Donelson and Pierce, Robert H and Thisted, Thomas and van der Horst, Edward H},
  title = {Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics},
  journal = {Antibodies},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {55},
  doi = {10.3390/antib12030055}
}
Kostenlos starten →